Nama's AI scorecard currently rates Inhibrx Biosciences Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does INBX report earnings?

Inhibrx Biosciences's next scheduled report is on Nov 13, 2026. Analysts expect EPS of -$2.35.

What is the INBX price target?

The median analyst price target from 3 analysts is $245.00, with a range of $230.00 – $325.00.

Is INBX Shariah compliant?

Nama's AAOIFI-style screen reads Inhibrx Biosciences as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Inhibrx Biosciences (INBX)

Healthcare · Biotechnology · NASDAQ

Inhibrx Biosciences (INBX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.24B and a free-cash-flow yield of -9.9%. Over the most recent reported fiscal year, revenue grew 550.0%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Middle · +15.3% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-45.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.24B
Trailing P/E	—
Price / book	—
Price / sales	—
FCF yield	-9.9%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	+550.0%
Revenue growth (3-yr annual)	-0.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	3.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

INBX earnings

Next report: Nov 13, 2026 (Q3 2026, EPS estimate -$2.35). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 13, 2026	-$2.34	-$2.28	-2.6%	$0
Q1 2026	May 14, 2026	-$2.15	-$1.20	-79.2%	$0
Q4 2025	Mar 19, 2026	-$2.11	-$2.08	-1.4%	$0
Q3 2025	Nov 14, 2025	-$2.28	-$1.72	-32.6%	$0

INBX analyst price target

Median target $245.00 from 3 analysts, ranging $230.00 – $325.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live INBX data on Nama Insights →

INBX FAQ

Is INBX a buy?: Nama's AI scorecard currently rates Inhibrx Biosciences Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does INBX report earnings?: Inhibrx Biosciences's next scheduled report is on Nov 13, 2026. Analysts expect EPS of -$2.35.
What is the INBX price target?: The median analyst price target from 3 analysts is $245.00, with a range of $230.00 – $325.00.
Is INBX Shariah compliant?: Nama's AAOIFI-style screen reads Inhibrx Biosciences as Can't Tell. A figure the screen needs is missing, so it can't tell.